Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
BW
-
Mannheim, BW, Germany, 68159
- Central Institute of Mental Health, Department of Psychiatry,
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Treatment resistant schizophrenic or schizoaffective disorder under therapy with clozapine,
- Age between 18 and 70,
- Informed consent
Exclusion Criteria:
- No informed consent,
- Intolerance with respect to ziprasidone or risperidone,
- Contraindications with respect to these substances,
- Gravidity or missing anticonceptive safety
- Substance dependance (excluded nicotin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
PANSS, SANS, HAMD, GAF, CGI, QTc
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Body weight, EPMS, Akathisia,Prolactin, blood pressure, heart rate
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mathias Zink, MD, Central Institute of Mental Health, Department of Psychiatry, Mannheim, Germany
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Psychotic Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Risperidone
- Ziprasidone
Other Study ID Numbers
Other Study ID Numbers
- CZR-zink
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.